Peptide Cancer Vaccine Market is estimated to be US$ 19.5 billion by 2032 with a CAGR of 12.9% over the forecast period (2022-2032)

 

Peptide are formed when condensation reaction takes place between carboxyl group of one amino acid & other amino group. Ribosomes are the site of synthesis of proteins. Peptide Synthesis and its applications are increasing due to development in bioengineering and biotechnology sector and also used for various research purposes which includes, antibiotic drug development, cancer diagnosis & treatment, mapping of epitope, production of vaccine & antibodies, etc. Solid Phase Peptide Synthesis (SPPS) method is carried out on solid support called as resin. The specific characters of peptide like high specificity, high bioactivity, and low toxicity has made them more attractive therapeutic agents. Peptides has ability to synthesize in solution medium on solid support and combination of solid & solution synthesis. Peptide Synthesis is carried out by solid-phase method. The solution method is preferred by pharmaceutical companies. Peptide cancer vaccines are designed which is based on epitope peptides that elicit humoral & cellular immune responses by targeting TAAs (tumor-associated antigens) or TSAs (tumor-specific antigens). Cancer has ranked second leading cause of death in the world. According to (PMC), around 10 million deaths are being reported in 2020. Peptide based vaccines is a vaccination approach which has minimal side-effects that uses synthetic tumor-associated, specific peptides, or combination of peptides that are designed to designed to elicit peptide-specific T cells. These type of peptides are present on surface of HLA (human leukocyte antigen) molecules for recognition of T cell receptors CD4 & CD8 T cells. Peptide based cancer vaccines possess various advantage over other therapies as they had shown benefits in treating metastatic cancers. Peptide based cancer vaccines can use multiple T cell epitopes which are positioned inside or outside of tumor cells. Peptide based cancer vaccines can be effectively help in inducing significant immune response for active immunotherapy. Peptide based cancer vaccines containing multiple epitopes could able to address the issue of antigen loss with greater flexibility. Personal neo-antigen vaccine is a new type of peptide-based cancer vaccine. Personal neo-antigen vaccine has shown to be safe, efficacious & robustly elicit T cell responses. Peptides are highly specific to elicit antigen specific T cell response & can employed in multiplexing strategies by targeting multiple epitopes. Peptide cancer vaccines has shown an increased focus in combination with standard treatment such as radiotherapy, chemotherapy, and other various immunotherapeutic approaches. Some peptide cancer vaccines are determined to be improved survivals with fewer side effects compared to conventional therapies. However, rising prevalence of cancer diseases has given positive impact on target market growth.

 

The report “Peptide Cancer Vaccine Market, By Type (Peptide-Pulsed Dendritic Cancer Vaccine, Personalized Peptide Vaccine, Multivalent Peptide Vaccine, and Others), and By Application (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

 

Key Highlights:

·         In November 2022, ISA Pharmaceuticals has announced the publication by Leiden University Medical Center (LUMC) of phase 1 clinical study by using ISA’s proprietary Amplivant adjuvant & SLP (Synthetic Long Peptide) therapeutic vaccine technology. SLPs conjugated to Amplivant has elicited the strong, significant, immune response & dose related systemic T cell immunity when injected intra-dermally. It has determined that SLPs conjugated to Amplivant has highly favorable tolerability & safety when used as intradermal therapeutic vaccine.

·         In April 2018, Boston Biomedical has initiated dosing of first patient in two of its clinical trials by determining DSP-7888 investigational cancer peptide vaccine. Boston Biomedical are exploring the potential of DSP-7888 to elicit an anti-tumor response in number of high unmet need tumor types. Boston Biomedical is currently conducting the early phase studies for analyzing DSP-7888 to treat patients with myelodysplastic syndrome, pediatric high grade gliomas, and malignant tumors.

 

Analyst View:

The key factor driving the growth of the Peptide Cancer Vaccine market is rising prevalence of cancer disease and rapid growth in urbanization. Peptide-based cancer vaccines has become attractive immunotherapeutic options because they are safe and inexpensive to produce. Peptide-based cancer vaccines can elicit cell mediated antitumor response by antigen presentation selected tumor epitopes to T cells. As peptide specific immunity has been decrease over time the peptide based vaccines targeting different tumor antigens is in need to overcome the resistance. However, more research & development is needed for establishing the effectiveness of combination therapies, identifying best combination and optimum dose scheduling for each component. As a result, market competition is intensifying, and both big international corporations and start-ups are vying to establish position in the market.

 

Free sample Report:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/5034

 

Key Market Insights from the report:

Peptide Cancer Vaccine Market accounted for US$ 5.41 billion in 2022 and is estimated to be US$ 19.5 billion by 2032 and is anticipated to register a CAGR of 12.9%. The Peptide Cancer Vaccine Market is segmented based on Type, Application and Region.

·         Based on Type, Peptide Cancer Vaccine Market is segmented into Peptide-Pulsed Dendritic             Cancer Vaccine, Personalized Peptide Vaccine, Multivalent Peptide Vaccine, and others.

·    Based on Application, Peptide Cancer Vaccine Market is segmented into Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, and others.

·    By Region, the Peptide Cancer Vaccine Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

 

Competitive Landscape & their strategies of Peptide Cancer Vaccine Market:

The prominent players operating in the Peptide Cancer Vaccine Market includes, Boston Biomedical, Immatics N.V., VAXON Biotech, GlaxoSmithKline PLC., ISA Pharmaceuticals, TapImmune, Ultimovacs, Generex Biotechnology, Onco Therapy Science Inc., Moderna Inc., and others.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.